摘要
目的目的探讨食管癌(EC)患者血清微管解聚蛋白(STMN)、血管内皮生长因子C(VEGFC)水平及临床意义。方法方法选取80例EC患者和60例健康体检者,分别作为EC组和健康组。比较两组患者及不同临床特征EC患者的血清STMN、VEGFC水平。随访3年,采用Cox回归模型分析EC患者预后的影响因素。结果结果EC组患者的血清STMN、VEGFC水平均明显高于健康组,差异均有统计学意义(P﹤0.01)。淋巴结转移、临床分期为Ⅲ期EC患者的血清STMN、VEGFC水平均明显高于无淋巴结转移、临床分期为Ⅰ~Ⅱ期的患者,差异均有统计学意义(P﹤0.01)。多因素Cox回归分析结果显示,血清STMN水平≥3.46 ng/ml、血清VEGFC水平≥1129.76 ng/L、低分化、淋巴结转移均是EC患者预后的独立危险因素(P﹤0.05)。结论结论EC患者血清VEGFC和STMN水平均较高,且其表达水平与EC患者的临床特征和预后有关。
Objective To investigate the levels of serum stathmin(STMN)and vascular endothelial growth factor C(VEGFC)in patients with esophageal cancer(EC)and their clinical significance.Method A total of 80 EC patients and 60 healthy subjects were selected as EC group and healthy group respectively.Serum STMN and VEGFC levels were compared between the two groups and EC patients with different clinical characteristics.Followed up for 3 years,Cox re-gression model was used to analyze the prognostic influencing factors of EC patients.Result The levels of serum STMN and VEGFC in EC group were significantly higher than those in healthy group,and the differences were statistical-ly significant(P<0.01).The levels of serum STMN and VEGFC in EC patients with lymph node metastasis and clinical stage III were significantly higher than those without lymph node metastasis and clinical stage I-II,and the differences were statistically significant(P<0.01).Multivariate Cox regression analysis results showed that serum STMN level≥3.46 ng/ml,serum VEGFC level≥1129.76 ng/L,low differentiation and lymph node metastasis were independent risk fac-tors for the prognosis of EC patients(P<0.05).Conclusion The levels of serum VEGFC and STMN are higher in EC pa-tients,and their expression levels are related to the clinical characteristics and prognosis of EC patients.
作者
李泮
陈光辉
赵明静
郭爱叶
LI Pan;CHEN Guanghui;ZHAO Mingjing;GUO Aiye(Department of Laboratory,He’nan Provincial People’sHospital,Zhengzhou 450003,He’nan,China)
出处
《癌症进展》
2024年第15期1697-1700,共4页
Oncology Progress
关键词
食管癌
微管解聚蛋白
血管内皮生长因子C
临床特征
预后
esophageal cancer
stathmin
vascular endothelial growth factor C
clinical characteristic
prognosis
